{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:55:49Z","timestamp":1794970549190,"version":"4.9.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,9]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Isolation and characterization of a high-affinity TCR targeting the intracellular B cell\u2013specific transcription factor BOB1. T cells expressing a BOB1-specific TCR lysed and eradicated primary multiple myeloma and other B-cell malignancies in vitro and in vivo.<\/jats:p>","DOI":"10.1182\/blood-2016-09-737536","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T22:00:24Z","timestamp":1483567224000},"page":"1284-1295","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":58,"title":["TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9880-7026","authenticated-orcid":false,"given":"Lorenz","family":"Jahn","sequence":"first","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pleun","family":"Hombrink","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"},{"name":"Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate S.","family":"Hagedoorn","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel G. D.","family":"Kester","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"van der Steen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Research and Development, Bellicum Pharmaceuticals, Inc., Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsvetelina","family":"Pentcheva-Hoang","sequence":"additional","affiliation":[{"name":"Research and Development, Bellicum Pharmaceuticals, Inc., Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud H.","family":"de Ru","sequence":"additional","affiliation":[{"name":"Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein P.","family":"Schoonakker","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda H.","family":"Meeuwsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Griffioen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"van Veelen","sequence":"additional","affiliation":[{"name":"Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam H. M.","family":"Heemskerk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111904335895400_B1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111904335895400_B2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111904335895400_B3","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111904335895400_B4","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111904335895400_B5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6059","key":"2019111904335895400_B6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/320232a0","article-title":"Transfer of specificity by murine alpha and beta T-cell receptor genes","volume":"320","author":"Dembi\u0107","year":"1986","journal-title":"Nature"},{"issue":"17","key":"2019111904335895400_B7","doi-asserted-by":"crossref","first-page":"8207","DOI":"10.1128\/JVI.74.17.8207-8212.2000","article-title":"Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes","volume":"74","author":"Cooper","year":"2000","journal-title":"J Virol"},{"issue":"7","key":"2019111904335895400_B8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nri841","article-title":"T-cell-receptor gene therapy","volume":"2","author":"Schumacher","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2019111904335895400_B9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2006.01.006","article-title":"Optimizing TCR gene transfer","volume":"119","author":"Heemskerk","year":"2006","journal-title":"Clin Immunol"},{"issue":"5796","key":"2019111904335895400_B10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"issue":"7","key":"2019111904335895400_B11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111904335895400_B12","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-11-1066","article-title":"PRAME-specific allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer","volume":"17","author":"Amir","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111904335895400_B13","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1182\/blood-2003-11-3903","article-title":"Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen","volume":"103","author":"Savage","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2019111904335895400_B14","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1172\/JCI43437","article-title":"MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors","volume":"120","author":"Leisegang","year":"2010","journal-title":"J Clin Invest"},{"issue":"15","key":"2019111904335895400_B15","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/blood-2011-06-357939","article-title":"TCR-transgenic lymphocytes specific for HMMR\/Rhamm limit tumor outgrowth in vivo","volume":"119","author":"Spranger","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111904335895400_B16","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/leu.2010.186","article-title":"Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif","volume":"24","author":"Abrahamsen","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2019111904335895400_B17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2014-07-587840","article-title":"Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b","volume":"125","author":"Jahn","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111904335895400_B18","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.1073\/pnas.111162298","article-title":"Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex","volume":"98","author":"Heemskerk","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"2019111904335895400_B19","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1073\/pnas.92.15.6733","article-title":"Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells","volume":"92","author":"Rivi\u00e8re","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2019111904335895400_B20","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1074\/mcp.M112.024810","article-title":"The human leukocyte antigen-presented ligandome of B lymphocytes","volume":"12","author":"Hassan","year":"2013","journal-title":"Mol Cell Proteomics"},{"issue":"5","key":"2019111904335895400_B21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1110\/ps.0239403","article-title":"Reliable prediction of T-cell epitopes using neural networks with novel sequence representations","volume":"12","author":"Nielsen","year":"2003","journal-title":"Protein Sci"},{"issue":"Web Server issue","key":"2019111904335895400_B22","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkn202","article-title":"NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11","volume":"36","author":"Lundegaard","year":"2008","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2019111904335895400_B23","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.4049\/jimmunol.1502400","article-title":"POU2AF1 functions in the human airway epithelium to regulate expression of host defense genes","volume":"196","author":"Zhou","year":"2016","journal-title":"J Immunol"},{"issue":"24","key":"2019111904335895400_B24","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.1005802107","article-title":"Mixed T cell receptor dimers harbor potentially harmful neoreactivity","volume":"107","author":"van Loenen","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2019111904335895400_B25","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1128\/MCB.18.12.7397","article-title":"Coactivator OBF-1 makes selective contacts with both the POU-specific domain and the POU homeodomain and acts as a molecular clamp on DNA","volume":"18","author":"Sauter","year":"1998","journal-title":"Mol Cell Biol"},{"issue":"20","key":"2019111904335895400_B26","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1101\/gad.13.20.2650","article-title":"Crystal structure of an OCA-B peptide bound to an Oct-1 POU domain\/octamer DNA complex: specific recognition of a protein-DNA interface","volume":"13","author":"Chasman","year":"1999","journal-title":"Genes Dev"},{"issue":"4","key":"2019111904335895400_B27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.cell.2006.03.036","article-title":"Nontranscriptional regulation of SYK by the coactivator OCA-B is required at multiple stages of B cell development","volume":"125","author":"Siegel","year":"2006","journal-title":"Cell"},{"issue":"5","key":"2019111904335895400_B28","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1128\/MCB.21.5.1531-1539.2001","article-title":"The B lymphocyte-specific coactivator BOB.1\/OBF.1 is required at multiple stages of B-cell development","volume":"21","author":"Hess","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"6600","key":"2019111904335895400_B29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/383538a0","article-title":"B-cell-specific coactivator OBF-1\/OCA-B\/Bob1 required for immune response and germinal centre formation","volume":"383","author":"Schubart","year":"1996","journal-title":"Nature"},{"issue":"6600","key":"2019111904335895400_B30","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/383542a0","article-title":"The B-cell-specific transcription coactivator OCA-B\/OBF-1\/Bob-1 is essential for normal production of immunoglobulin isotypes","volume":"383","author":"Kim","year":"1996","journal-title":"Nature"},{"issue":"12","key":"2019111904335895400_B31","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/eji.1830261255","article-title":"B lymphocytes are impaired in mice lacking the transcriptional co-activator Bob1\/OCA-B\/OBF1","volume":"26","author":"Nielsen","year":"1996","journal-title":"Eur J Immunol"},{"issue":"1","key":"2019111904335895400_B32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4049\/jimmunol.164.1.18","article-title":"Cutting edge: lack of peripheral B cells and severe agammaglobulinemia in mice simultaneously lacking Bruton\u2019s tyrosine kinase and the B cell-specific transcriptional coactivator OBF-1","volume":"164","author":"Schubart","year":"2000","journal-title":"J Immunol"},{"issue":"1","key":"2019111904335895400_B33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.onc.1210637","article-title":"POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17","volume":"27","author":"Zhao","year":"2008","journal-title":"Oncogene"},{"issue":"8","key":"2019111904335895400_B34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"issue":"5","key":"2019111904335895400_B35","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.4049\/jimmunol.1100852","article-title":"Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity","volume":"187","author":"Falkenburg","year":"2011","journal-title":"J Immunol"},{"issue":"11","key":"2019111904335895400_B36","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/eji.201343397","article-title":"Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire","volume":"43","author":"Hombrink","year":"2013","journal-title":"Eur J Immunol"},{"issue":"6","key":"2019111904335895400_B37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111904335895400_B38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"issue":"5319","key":"2019111904335895400_B39","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"issue":"11","key":"2019111904335895400_B40","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1182\/blood-2006-05-023416","article-title":"Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation","volume":"109","author":"Ciceri","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111904335895400_B41","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111904335895400_B42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1073\/pnas.0710198105","article-title":"A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer","volume":"105","author":"Kieback","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019111904335895400_B43","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"issue":"18","key":"2019111904335895400_B44","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"issue":"20","key":"2019111904335895400_B45","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111904335895400_B46","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/eji.200636900","article-title":"CD8alpha\/alpha homodimers fail to function as co-receptor for a CD8-dependent TCR","volume":"37","author":"McNicol","year":"2007","journal-title":"Eur J Immunol"},{"issue":"5","key":"2019111904335895400_B47","doi-asserted-by":"crossref","first-page":"e65212","DOI":"10.1371\/journal.pone.0065212","article-title":"Extracellular domains of CD8\u03b1 and CD8\u00df subunits are sufficient for HLA class I restricted helper functions of TCR-engineered CD4(+) T cells","volume":"8","author":"van Loenen","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2019111904335895400_B48","doi-asserted-by":"crossref","first-page":"976","DOI":"10.4049\/jimmunol.177.2.976","article-title":"Generation of T cell help through a MHC class I-restricted TCR","volume":"177","author":"Kessels","year":"2006","journal-title":"J Immunol"},{"issue":"6230","key":"2019111904335895400_B49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/10\/1284\/1399333\/blood737536.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/10\/1284\/1399333\/blood737536.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:34:16Z","timestamp":1574138056000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/10\/1284\/36033\/TCRbased-therapy-for-multiple-myeloma-and-other"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,3,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-737536","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}